Monday, August 3, 2020 Daily Archives

Thermo and Lyell team to boost T-cell fitness for CAR-T

Thermo Fisher Scientific will develop manufacturing processes for cancer cell therapies in collaboration with Lyell Immunopharma. The deal – financial terms of which were not provided – will focus on improving the “fitness” of T cells from which cell therapies are produced according to the firms. A T-cells metabolic “fitness” describes the likelihood it can be turned into a cell therapy. Cell therapies need to be fit because of the high metabolic demands of tumor cells can negatively impact their…

MolMed latest add-on for expansion hungry AGC Biologics

AGC Biologics has acquired Molecular Medicine (MolMed), increasing its presence in the CDMO space and adding a pipeline of cell and gene therapy candidates. In March, contract development and manufacturing organization (CDMO) AGC Biologics launched a voluntary tender offer to acquire Italian cell and gene therapy developer and manufacturer MolMed for €240 million ($284 million). Today the deal has been completed, bulking out AGC’s biopharma offering. On the services side, AGC adds two GMP sites in Milan and Bresso, both…